Page 1

✗Arecor Arecor Therapeutics plc ( " Arecor " , the " Company " or the " Group " ) Interim results for the six months to 30 June 2026 Cambridge , UK , 30 September 2026 : Arecor Therapeutics plc ( AIM : AREC ) , a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes , obesity and other cardiometabolic diseases , reports its unaudited interim results for the six months ended 30 June 2026 . Operational highlights • Diabetes ( Arecor Insulins ) ° ° ° Partnering discussions with multiple insulin pump companies to bring the Arecor insulin - AID combination to market are at term sheet stage Co - development of AT278 to Phase 2 readiness continues with partner Sequel Med Tech , with positive on - going agreement negotiations in parallel Arecor has had continuing positive interactions with the US Food and Drug Administration ( FDA ) on the design of the Phase 2 clinical study for its concentrated ultra - rapid - acting insulin in combination with an AID ( Automated Insulin Delivery ) system . This provides confidence on the Phase 2 study design for either AT278 ( U500 ) or AT290 ( U200 ) which is a six - week crossover study in people with Type 1 and Type 2 diabetes comparing Arecor insulin against NovoLog® , in approximately 90 subjects , with time - in - range as the primary endpoint Obesity ( Oral GLP - 1 receptor agonist ) ° Whilst the primary focus has been on the Group's proprietary insulin portfolio , generation of pre - clinical data to assess bioavailability of Arecor's oral GLP - 1 candidate continues . Royalty Financing Agreement Post period - end • • In 1H 26 Arecor received a $ 0.5 million payment from Ligand Pharmaceuticals ( " Ligand " ) . A further $ 0.5 million payment from Ligand has been received during 2H 26 under the royalty financing agreement announced in September 2025. An additional $ 3.0 million is payable upon the achievement of certain commercial milestones related to AT220 and AT292 . The Company is today launching a Fundraising to raise up to £ 5.13 million , details of which can be found in a separate announcement . Publication of clinical data from the AT278-104 study published in the peer - reviewed Diabetes , Obesity & Metabolism , reinforcing our potential to enable next - generation AID systems . Financial highlights ( unaudited ) Revenue £ 0.2 million ( 1H 2025 : £ 1.0 million restated ) • R & D costs of £ 1.9 million ( 1H 2025 : £ 1.3 million ) • Loss after tax of £ 3.0 million ( 1H 2025 : £ 2.0 million restated ) Cash , cash equivalents and short - term investments of £ 3.2 million at 30 June 2026 ( at 30 June 2025 : £ 1.9 million ) Sarah Howell , Chief Executive Officer of Arecor , commented : " Arecor's focus remains on our two core product areas : diabetes and the oral delivery of peptides , where there remains high unmet patient need that Arecor aims to address in large multi - billion - dollar markets . Within diabetes , Arecor has the potential to have the only concentrated ultra - rapid - acting insulins which can catalyse the next generation of longer wear , miniaturised and fully closed loop Automated Insulin Delivery